article thumbnail

Abiogen acquires EffRx to fortify bone disease portfolio

Pharmaceutical Technology

Bisphosphonates are drugs that slow the progression of bone loss. EffRx has received several European regulatory approvals for drugs in its portfolio. Alkindi is one of EffRx’s three marketed drugs. In Italy, Abiogen began distributing its bisphosphonates in 2014 and has since seen some successful drug approvals.

article thumbnail

Leading clinical packaging companies in contract marketing

Pharmaceutical Technology

Unlike commercial pharmaceutical packaging, the primary consideration in clinical trial packaging is protecting the product quality and reliability for research. Finding the best clinical trial packaging services providers.

Packaging 100
article thumbnail

J&J’s Carvykti and BMS’ Abecma Win FDA Approvals for Earlier Use in Multiple Myeloma

XTalks

After backing from the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) last month, Johnson and Johnson (J&J) and Bristol Myers Squibb (BMS) scored FDA approvals for the use of their B-cell maturation antigen (BCMA)-targeting CAR T-cell therapies as earlier line treatment options for multiple myeloma.